Trial Profile

Expression/DNA Methylation of Cancer Testis Antigens May Predict Response to Pembrolizumab in Non-small Cell Lung Cancer Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

04 Dec 2022 Status changed from recruiting to completed.
09 Jun 2020 Status changed from not yet recruiting to recruiting.
14 Aug 2018 Planned initiation date changed from 15 Jul 2018 to 15 Sep 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com